1. Sweden Stocks

  2. •

    Financial Services

  3. •

    Asset Management
MedCap AB (publ)

MedCap AB (publ)

MCAP.ST
MedCap AB (publ)SE flagStockholm Stock Exchange
526.50
SEK
-18.50
- -
7.91BMarket Cap
MedCap AB (publ)
MCAP.ST
(Stockholm Stock Exchange)

Recent

price

526.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
27.17
26.44
28.81
68.18
63.84
60.96
63.55
30.68
52.8
56.29
56.96
61.9
75.06
107.2
121.93
140.67
127.61
Revenue per Share
1.16
0.92
1.41
1.87
0.64
1.45
0.01
0.16
0.04
3.99
4.24
6.52
7.94
11.63
14
14.67
13.32
Basic EPS, GAAP
1.43
0.77
1.66
-2.03
-1.14
-2.07
3.34
0.69
4.2
3.06
6.35
3.74
2.78
12.74
19.82
18.72
17.93
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.51
0.34
1.49
3.55
3.71
5.19
3.95
3.15
4.94
9.04
12.77
18.11
27.55
39.3
53.29
65.68
- -
Book Value per Share
2.93
1.73
2.28
3.81
7.99
7.75
5.92
4.21
-2.88
-1.46
10.01
17.55
28.18
25.52
41.91
15.34
43.22
Tangible Book Value per Share
12
12
12
12
13
13
13
13
13
13
14
15
15
15
15
15
15
Basic Weighted Avg Shares
316
307
349
826
853
817
852
411
709
757
817
916
1,111
1,587
1,807
2,108
1,903
Sales/Revenue/Turnover
8.33
4.06
6.98
3.31
4.41
3.44
0.2
3.55
6.28
10.43
9.86
11.78
13.42
13.57
13.34
13.7
13.93
Operating Margin (%)
11
15
21
25
20
23
27
30
34
57
68
76
88
104
115
153
126
Depreciation Expense
14
11
17
23
9
19
- -
2
1
54
61
96
118
172
207
220
199
Net Income, GAAP
25.65
19.24
22.43
1.59
19.51
15.2
- -
58.62
34.33
20.22
20.86
16.15
22.37
22.4
19.99
23.63
20.92
Effective Tax Rate (%)
4.28
3.48
4.9
2.74
1
2.38
0.01
0.51
0.08
7.09
7.45
10.53
10.58
10.85
11.48
10.43
10.44
Profit Margin (%)
60
44
62
70
114
141
71
80
17
-22
166
233
440
422
586
497
608
Working Capital
23
20
23
29
12
55
19
49
65
158
157
165
224
192
297
381
273
LT Debt
180
170
195
222
281
308
292
268
274
333
602
698
859
1,027
1,288
1,459
1,363
Total Equity
8.73
4.51
7.6
7.72
7.12
5.17
- -
1.35
6.49
11.29
8.22
9.78
10.57
13.04
12.7
11.97
12.74
Return on Invested Capital (%)
14.98
20.49
23.74
15.15
4.84
9.67
- -
1.38
0.47
17.24
14.63
20.98
20.35
23.03
22.02
18.49
60.12
Return on Capital (%)
- -
- -
154.82
73.95
18.4
32.66
0.12
4.42
1.11
57.16
39.95
42.76
34.79
34.79
30.24
24.78
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
61
62
62
LT Borrowings
49
43
37
LT Finance Leases
249
243
237
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
8,906
5,112
6,680

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
918
912
979
Cash, Cash Equivalents & STI
370
315
335
Accounts Receivable, Net
211
289
310
Inventories
269
289
300
Total Current Liabilities
332
341
371
Payables & Accruals
- -
- -
- -
ST Debt
61
62
62
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.84%
19.45%
13.25%
Free Cash Flow
60.49%
68.86%
-4.49%
Net Income, GAAP
1,162.22%
30.64%
5.98%
Sales/Revenue/Turnover
14.64%
21.34%
16.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
462
458
413
474
1,807
2025
494
522
591
- -
2,108
2026
557
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.78
3.84
3.57
2.8
14
2025
3.37
3.57
4.31
- -
14.67
2026
3.72
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Calamos Russell 2000 Structured Alt Protection ETF – October (CPRO)
SMI 3Fourteen Full-Cycle Trend ETF (FCTE)
Value Partners Group Limited (0806.HK)
Fidelity Growth Strategies Fund (FDEGX)
Praxis Impact Large Cap Value ETF (PRXV)
Fidelity US Equity Research Enhanced UCITS ETF ACC-USD (FUSS.L)
Business
MedCap AB (publ) (MCAP.ST) is a Sweden-based investment company that acquires, develops and owns profitable niche companies within the life science sector, focusing on assistive technology, medical technology (MedTech) and specialty pharmaceuticals. Founded in 2001 and headquartered in Solna, Stockholm, the group operates primarily in Northern Europe, with sales distributed across Sweden (50%), other Nordic countries (25%), broader Europe (21%) and the rest of the world (4%); its portfolio companies serve regions, municipalities, healthcare providers, property owners and end-users. Core offerings span three business areas: Assistive Tech, including digital and physical aids for cognition, communication, environmental control, alarms, mobility, accessibility and orthotics through subsidiaries such as Abilia (Nordic, UK, exports), Trident (Sweden, Europe), Huka (Benelux, Nordic, Germany, USA), Erimed (Nordic, exports) and Danrehab (Nordic, Benelux, Europe); MedTech, encompassing medical devices, healthcare equipment, packaging solutions for life science products, contract manufacturing of probiotics and nutrition supplements, carbon fiber components and clean air equipment for operating rooms via companies like Inpac (Nordic), Multi-Ply (global), SurgiCube (global), Toul Meditech (global) and Cardiolex (Europe); and Specialty Pharma, featuring specialty pharmaceuticals, contract development and manufacturing organization (CDMO) services and medicines in licensed, extemporaneous and non-licensed classifications through Unimedic (Northern Europe). In 2025, MedCap completed three key acquisitions to drive growth and expand offerings: Danrehab in Assistive Tech, XGX Pharma in Specialty Pharma on July 21 (enhancing registered pharmaceuticals and commercial portfolio via Unimedic collaboration), and LivAssured by subsidiary Abilia on October 1 (adding Nightwatch epileptic seizure detection device, initially for EUR 9.5 million plus deferred and potential earn-out payments up to EUR 4 million); these moves contributed to Q3 2025 net sales growth of 21% (9% organic), adjusted EBITA up 32% to SEK 91.1 million and strengthened market positions across segments.